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Aims ENSURE-AF (NCT 02072434) was the largest prospective randomized clinical trial of anticoagulation for cardiover-
sion in atrial fibrillation (AF), which also provides the largest prospective dataset for transoesophageal echocardiog-
raphy (TOE) prior to cardioversion. This ancillary analysis investigated determinants of TOE-detected left atrium




The ENSURE-AF multicentre PROBE evaluation trial compared edoxaban 60 mg once daily (QD) with enoxaparin/
warfarin in 2199 subjects undergoing ECV of non-valvular AF. Patients were stratified by the use of TOE, anticoag-
ulant experience, and selected edoxaban dose. Electrical cardioversion was cancelled or deferred when
TOEdetected LAT. In total, 1183 subjects were stratified to the TOE arm and LAT was reported in 91 (8.2%). In
univariate analysis, age >_75 years (26.4% vs. 16.9%, P = 0.0308), lower weight (86.5 ± 15.0 vs. 90.7 ± 18.0 kg,
P = 0.0309), lower creatinine clearance (80.1 ± 30.6 vs. 93.2 ± 33.9 mL/min, P = 0.0007), heart failure (59.3% vs.
43.0%, P = 0.0029), and diuretic treatment (53.9% vs. 40.1%, P = 0.0141) were more prevalent in the LAT group.
Non-significant trends were seen for higher mean CHA2DS2-VASc score (3.0 ± 1.41 vs. 2.7 ± 1.48, P = 0.0571) and
more prevalent anticoagulation use prior to enrolment (60.4% vs. 50.3%, P = 0.0795) in the LAT group. In logistic
regression analysis, age (P = 0.0202) and heart failure (P = 0.0064) were independently associated with LAT.
...................................................................................................................................................................................................
Conclusion Elective ECV is commonly cancelled or deferred due to TOE-detected LAT in patients with non-valvular AF. Age
>_75 years and heart failure were associated with the presence of LAT.
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Potential risk factors for stroke in patients with atrial fibrillation (AF)
have been thoroughly studied and are well established.1 Stroke, how-
ever, may result from different mechanisms, such as left atrial thrombi
(LAT) embolization or local brain thrombosis. Risk factors for LAT
formation are not well understood and are not necessarily the same
as the risk factors for stroke in patients with AF.2 The theory of endo-
cardial remodelling describes the underlying molecular pathophysiol-
ogy of atrial thrombogenesis in AF.3 Main factors of this process
appear to be oxidative stress and inflammation in the fibrillating atrial
tissue, which cause up-regulation of thrombogenic proteins at the en-
docardial surface. Furthermore, concomitant diseases and conditions
such as ageing, arterial hypertension, diabetes mellitus, or congestive
heart failure appear to have an important impact. Recognition of
these factors is potentially important, especially for patients who are
scheduled for cardioversion because the procedure may result in
thrombi dislodgement and embolization.4
Multiple studies have reported the incidence of LAT in several clin-
ical settings, including prior to AF cardioversion.5–8 These reports in-
clude prospective trials in the setting of cardioversion, as well as
single-centre retrospective studies, which found different risk factors
for LAT.9,10 The ENSURE-AF study (NCT 02072434) is the largest
prospective, multicentre, randomized clinical trial of anticoagulation
for cardioversion in non-valvular AF and demonstrated a comparable
efficacy and safety of the oral factor Xa inhibitor edoxaban vs. enoxa-
parin–warfarin.11 This randomized trial also provides the largest pro-
spective dataset for transoesophageal echocardiography (TOE) prior
to cardioversion in this clinical setting.
The aim of this ancillary analysis was to investigate clinical determi-
nants of TOE-detected LAT in patients scheduled for electrical car-
dioversion (ECV) of AF.
Methods
Study design
The ENSURE-AF trial design has been described elsewhere in detail.12 In
brief, this was an open-label, randomized, multicentre, multinational,
parallel-group study comparing edoxaban 60 mg QD with optimized anti-
coagulation by enoxaparin–warfarin in subjects with indication for ECV of
AF.
The primary efficacy endpoint was the composite of stroke, systemic
embolic event, myocardial infarction, and cardiovascular death from
randomization until end of study, and the primary safety endpoint was
the composite of major and clinically relevant non-major bleeding after
TOE- or non–TOE-guided cardioversion in both treatment arms.
The study was conducted in compliance with the protocol, the ethical
principles as outlined in the Declaration of Helsinki, the International
Conference on Harmonization (ICH) consolidated Guideline E6 for
Good Clinical Practice (CPMP/ICH/135/95), and applicable regulatory
requirements. The protocol and its amendments were approved by
ethics committees or institutional review boards. All patients provided
written informed consent prior to participation in the study.
To comply with the Transparency and Openness Promotion
Guidelines, data presented in this manuscript can be obtained from the
corresponding author.
Patients
Patients were enrolled if they had ongoing non-valvular AF lasting for
>_48 h but <_12 months, and were scheduled for ECV. Exclusion criteria
included recent acute coronary syndrome or coronary intervention,
thrombus or mass in the left cardiac chambers, left atrial appendage
exclusion, mitral valve rheumatic disease or mechanical heart valve,
formal indication for conventional anticoagulation, active or high-risk
bleeding, severe renal insufficiency (calculated creatinine clearance
[CrCl] <30 mL/min), treatment with dual antiplatelet therapy, or con-
traindication for anticoagulant agents. The sample size calculation for
the main trial has been reported elsewhere, 11 and the present study
represents a pre-specified ancillary analysis of those patients with left
atrial thrombus present.
At randomization, all subjects were stratified based on the approach
to cardioversion (TOE vs. non-TOE). The decision to enrol the patient in
the TOE or non-TOE stratum was left to the local investigators.
Treatment and transoesophageal
echocardiography
The study treatment with either edoxaban or enoxaparin–warfarin was
started on the day of randomization and continued until day of ECV.
Patients randomized to edoxaban received 60 mg once daily (QD) ex-
cept for those with CrCl <50 mL/min, low body weight (<_60 kg), or con-
comitant use of P-glycoprotein inhibitors (with the exception of
amiodarone) who received 30 mg of edoxaban. Patients randomized to
warfarin also received enoxaparin until they had international normalized
ratio (INR) >_2.0. Both TOE and ECV were performed on the same day
and within 3 days after randomization (Figure 1). Cardioversion was per-
formed at least 2 h after the first dose of edoxaban or enoxaparin-
warfarin. If LAT were identified during the TOE procedure, the patient
was considered not eligible for subsequent cardioversion and the proce-
dure was cancelled or postponed.
Statistical analysis
This ancillary analysis included all randomized patients in the TOE stra-
tum who performed the TOE procedure. The data for patients in the
non-TOE stratum can be found elsewhere.11 Patients were divided into
two groups based on whether thrombi were identified by TOE.
Demographic, clinical characteristics and prior anticoagulant treatment
were summarized by TOE finding. Numerical variables were described as
mean with standard deviation. Categorical variables were described by
numbers and percentages of patients in each category. Data were com-
pared using one-way analysis of variance for numerical data and Fisher’s
exact test for categorical data. A logistic regression analysis with TOE
finding as the response variable was performed. The independent varia-
bles included the demographic and baseline characteristics, which
showed difference between LAT found and no LAT found groups
What’s new?
• The prevalence of left atrial thrombi (LAT) was found high in a
contemporary population from the largest trial on electrical
cardioversion (ECV) of atrial fibrillation.
• Age and heart failure, but not the CHA2DS2-VASc score,
were predictive of LAT.
• Left atrial thrombus was found in some patients despite opti-
mal anticoagulation but this did not appear to necessarily
translate to the development of systemic embolism in case of
ECV.
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(P < 0.1). Interaction term was not included in the analysis. Body weight
and CrCl were excluded in the analysis due to their high correlations
with age. Odds ratios and associated P-values were calculated.
Results
Some patients were excluded from the analysis because they did not
receive at least one dose of the study drug (36 patients); converted
spontaneously to sinus rhythm (20 patients); discontinued study
treatment before TOE procedure (10 patients); or had TOE can-
celled due to protocol deviation (1 patient), technical problem (1 pa-
tient), it was not tolerated (1 patient), or unknown reason
(1 patient). The remaining TOE patients (n = 1113, 97.04%) finally
had a TOE performed before ECV, and comprised the population
used for the present analysis (Figure 2). The characteristics of these
patients compared with those enrolled in the non-TOE stratum of
the main study, which was not included in the present analysis, can
be found elsewhere.11 LAT was found in 91 patients (8.2%). All
these patients had ECV cancelled or delayed until LAT resolution
was demonstrated. Demographic data of patients with and without
LAT at TOE are shown in Table 1. Univariate analysis showed that
age >_75 years (26.4% vs. 16.9%, P = 0.0308), lower weight
(86.5 ± 15.0 vs. 90.7 ± 18.0, P = 0.0309), lower CrCl (80.1 ± 30.6 vs.
93.2 ± 33.9, P = 0.0007), heart failure (59.3% vs. 43.0%, P = 0.0029),
and diuretic treatment (53.9% vs. 40.1%, P = 0.0141) were more
prevalent in the LAT group. Compared with patients with no LAT,
those with LAT had a higher mean CHA2DS2-VASc score (3.0 vs.
2.7), but the differences were not statistically significant
(P = 0.057); see Table 1.
Multivariable analysis showed that only age [odds ratio (OR):
1.055, P = 0.0013] and heart failure (OR: 1.97, P = 0.0064) were
independently associated with the detection of LAT on TOE. Age
>_75 years (OR: 2.13, P = 0.0202) and heart failure were associ-
ated with the presence of LAT, which was found in 12.2% and
10.9% of patients with these variables, respectively. Left atrium
thrombus was found in 6.0%, 7.3%, and 5.4% of patients with no
heart failure, age <75 years, or both, respectively. In contrast,
LAT was found in 18.7% of patients with heart failure and age
>_75 years (Figure 3).
Relationship to prior anticoagulation
The prevalence of LAT was not significantly different in relation to
the anticoagulation use in the 30 days prior to TOE (Table 2).
Compared with patients with no LAT, those with LAT were
more frequently treated with vitamin K antagonists in the 30 days
prior to enrolment; see Tables 1 and 2. No statistical differences



















Figure 1 Study design of the TOE stratum of the ENSURE-AF trial. ECV, electrical cardioversion; TOE, transoesophageal echocardiography.
LAT not found = 1022 (91.8%) LAT found = 91 (8.2%)
Randomized = 2199
(ITT analysis set)
Received ≥1 dose of study drug = 1147
(Safety analysis set)
TOE performed prior to ECV = 1113 (97%)
Non-TOE stratum = 1016TOE stratum = 1183
Figure 2 CONSORT figure for the TOE stratum of the
ENSURE-AF trial. ECV, electrical cardioversion; ITT, intention-to-
treat; LAT, left atrium thrombi; TOE, transoesophageal
echocardiography.










The main findings of this analysis, from a contemporary trial popula-
tion, are the prevalence of LAT in patients scheduled for ECV. Age
and heart failure, but not the CHA2DS2-VASc score, were predictive
of LAT. Other studies have reported slightly lower and higher rates
of LAT in patients scheduled for ECV of AF. However, most of these
studies are single-centre retrospective cohorts or had low numbers
....................................................................................................................................................................................................................
Table 1 Demographic and clinical data of patients with and without LAT detected by TOE performed for electrical
cardioversion of AF
LAT found (n 5 91) No LAT found (n 5 1022) P-value
Age (year)
Mean ± SD 67.3 ± 9.4 64.2 ± 10.8 0.0095
65–74 33 (36.3) 357 (34.9) 0.8191
>65 53 (58.2) 500 (48.9) 0.1007
>_75 24 (26.4) 173 (16.9) 0.0308
Male 55 (60.4) 678 (66.3) 0.2515
Weight (kg)
Mean ± SD 86.5 ± 15.05 90.7 ± 18.0 0.0309
<_60 kg 1 (1.1) 26 (2.5) 0.7188
BMI (mean ± SD) 29.9 ± 5.1 30.4 ± 5.5 0.4312
CHA2DS2-VASc score (mean ± SD) 3.0 ± 1.4 2.7 ± 1.5 0.0571
HAS-BLED score (mean ± SD) 1.0 ± 0.8 0.9 ± 0.8 0.3713
Current VKA user 50 (54.9) 469 (45.9) 0.1011
Current NOAC user 14 (15.4) 181 (17.7) 0.6669
CrCl (mL/min) 80.1 ± 30.6 93.2 ± 33.9 0.0007
TtTR (days) 6.4 ± 3.3 7.6 ± 5.1 0.2658
TiTR (% of time) 74.5 (32.2) 72.1 (28.9) 0.6279
TTR (% of time) 62.1 (34.2) 57.5 (33.2) 0.4219
Medical history
CHF 54 (59.3) 439 (43.0) 0.0029
CAD 17 (18.7) 174 (17.0) 0.6647
Diabetes 19 (20.9) 188 (18.4) 0.5740
Hypertension 68 (74.7) 825 (80.7) 0.1708
Myocardial infarction 4 (4.4) 63 (6.2) 0.6477
Valvular heart disease 20 (22.0) 302 (29.5) 0.1477
Peripheral artery disease 8 (8.8) 48 (4.7) 0.1254
Ischaemic stroke/TIA 4 (4.4) 78 (7.6) 0.3989
Intracranial bleeding 0 1 (0.1) 1.0000
Life-threatening bleed 1 (1.1) 2 (0.2) 0.2260
AF history
Paroxysmal (<_7 days) 17 (18.7) 233 (22.8) 0.4321
Persistent (>7 days, <1 year) 74 (81.3) 789 (77.2)
Drug treatmenta
Aspirin 18 (19.8) 194 (19.0) 0.8892
Lipid-modifying agents 33 (36.3) 392 (38.4) 0.7365
Beta blockers 75 (82.4) 797 (78.0) 0.3556
ACEI/ARB 52 (57.1) 660 (64.6) 0.1718
Diuretics 49 (53.8) 410 (40.1) 0.0141
VKA/NOAC 55 (60.4) 515 (50.3) 0.0795
P-values are from 1-way ANOVA model for numerical data and Fisher’s exact test for categorical data. Data reported as n (%) unless otherwise noted.
aDuring the 30 days before enrolment.
ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blockers; BMI body mass index; CAD, coronary artery disease; CHA2DS2-
VASc, congestive heart failure, hypertension, age >_75, diabetes mellitus, and prior stroke or transient ischaemic attack or thromboembolism, vascular disease, age 65–74 years,
sex category; CHF, congestive heart failure; CrCl, creatinine clearance; HAS-BLED, hypertension, abnormal renal and liver function, stroke, bleeding history or disposition, labile
INR, elderly, drugs or alcohol; INR, international normalized ratio; LAT, left atrium thrombi; NOAC, non-vitamin K antagonist oral anticoagulant; SD, standard deviation; TIA,
transient ischaemic attack; TiTR, time in treatment range; TTR, time in treatment range calculated using the Rosendaal method; TtTR, time to treatment range; TOE, transoeso-
phageal echocardiography; VKA, vitamin K antagonist.
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of patients.5–8,13,14 Other randomized trials—such as the ACUTE
trial, which enrolled 1222 patients with AF for ECV—included 549
patients who underwent TOE prior to ECV and found a higher rate
of LAT (13.8%).15 However, this trial was terminated almost 20 years
ago when the use of oral anticoagulation was less common and the
non-VKA oral anticoagulants were not available. More recent trials,
such as the X-VeRT trial,16 found LAT in 2.7% in 564 patients who
underwent TOE prior to ECV of AF. The population of this trial was
slightly younger, with lower prevalence of heart failure and prior
stroke than that included in the ENSURE-AF trial, which may explain
the three-fold higher prevalence of LAT in the ENSURE-AF trial.16
Data evaluating TOE prior to ECV of AF were obtained from more
than 1100 patients from 239 study sites in 19 countries in Europe and
the US in the ENSURE-AF trial. Therefore, it provides a contempo-
rary and well-represented sample of the general population of
patients scheduled for ECV. In addition, the EMANATE trial,17 which
studied 840 patients with TOE prior to ECV of AF, found LAT in
7.3%, a figure similar to the present study. Age (64.5± 12.8 and
64.7 ± 12.2 years for heparin/warfarin and apixaban, respectively) and
CHA2DS2-VASc score (2.4± 1.7 and 2.4± 1.7 for heparin/warfarin
and apixaban, respectively) were slightly lower in the general popula-
tion enrolled in the EMANATE trial compared with the ENSURE
trial.
Older age and heart failure were the only independent factors as-
sociated with LAT in this study. These were also among the most
powerful determinants of LAT in a recent meta-analysis in patients
with non-valvular AF.7 In contrast, previous stroke is the most pow-
erful risk factor for stroke in the general population of patients with
AF. This emphasizes that risk factors for stroke in AF are not neces-
sarily the same as those for LAT development in AF patients sched-
uled for ECV. Some studies,5,13,14 but not others,18 have found the
CHADS2 and CHA2DS2-VASc scores are the best determinants of
LAT prior to ECV. Although there was a trend toward higher
CHA2DS2-VASc in the present study, this was not statistically
significant.
In addition, patients already treated with warfarin in the previous
30 days had significant higher prevalence of LAT than those naı̈ve to
it. Several factors could explain this apparent paradox. One reason
could be that the decision of enrolment of patients in the TOE or
non-TOE strata was left to the investigator; hence, there could be a
potential bias that patients with higher perceived risk were placed in
the TOE stratum despite prior optimal or close-to-optimal anticoa-
gulation due to the fear of potential LAT. Indeed, patients enrolled in
the TOE stratum have significantly higher CHA2DS2-VASc score
than those enrolled in the non-TOE stratum.19 This probably was
not the case for those not already treated with warfarin—either be-
cause of a low-risk profile or first AF episode—who could be equally
enrolled in the TOE or non-TOE strata.
Left atrium thrombus was found in some patients despite optimal
anticoagulation, as was found in other studies.13,14 This raises con-
cerns about the safety of the non-TOE approach for ECV compared
with the TOE approach. Indeed, there were non-significant trends to-
wards lower cardiovascular events in the TOE strata compared with
the non-TOE strata despite more cardiovascular risk factors in the
former.19
Limitations
The main limitation of this study is that the decision to enrol patients
in the TOE or non-TOE strata was left to the investigator. Therefore,
the incidence of LAT in patients scheduled for ECV may have been
overestimated due to the potential bias of patients with worse risk
profile enrolled in the TOE stratum. A second limitation comes from
an inconsistent follow-up of INR levels, time in therapeutic range and
duration of anticoagulation before patient enrolment. Therefore, this
study does not clarify the risk of LAT formation despite proper anti-
coagulation regime at the time of ECV and is unclear if age and heart
failure will be more important determinants. Finally, TOE could have
been performed up to 72 h after anticoagulation initiation. This may
have resulted in some LATs having resolved prior to the TOE.
No HF or Age
>75


















Figure 3 Prevalence of LAT according to age and history of heart
failure in TOE stratum of the ENSURE-AF trial. HF, heart
failure; LAT, left atrium thrombi; TOE, transoesophageal
echocardiography.
.................................................................................................
Table 2 Differences in anticoagulation treatment
between patients with and without LAT detected by








Experienced 69 (75.8) 745 (72.9) 0.6221
Naı̈ve 22 (24.2) 277 (27.1)
Prior 30-day anticoagulation 55 (60.4) 514 (50.3) 0.0795
VKA, n (%) 43 (47.3) 340 (33.3) 0.0081
NOAC, n (%) 14 (15.4) 183 (17.9) 0.6671
INR at enrolmenta
Mean ± SD 1.6 ± 0.7 1.5 ± 0.6 0.3381
>_2, n (%) 22 (27.2) 213 (23.5) 0.4955
Suboptimal anticoagulation was defined as missing >_1 dose of NOAC or enoxa-
parin-warfarin with INR <2.
aDenominators are the number of patients who took VKAs.
AF, atrial fibrillation; INR, international normalized ratio; LAT, left atrium
thrombi; NOAC, non-vitamin K antagonist oral anticoagulant; SD, standard devia-
tion; TOE, transoesophageal echocardiography; VKA, vitamin K antagonist.










Elective ECV is commonly cancelled or deferred due to occurrence
of TOE-detected LAT in patients with non-valvular AF. Age
>_75 years and heart failure are associated with the presence of LAT
in these patient populations.
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